[Results of very high cyclophosphamide dosage in 42 patients with solid and lymphoreticular tumors].
D000505:Alopecia / Q000139:chemically induced; D000932:Antiemetics / Q000627:therapeutic use; D001798:Blood Proteins / Q000032:analysis; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D001856:Bone Marrow Examination; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D003556:Cystitis / Q000139:chemically induced; D004906:Erythrocyte Count; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D006452:Hemoglobinometry; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced; D005719:gamma-Globulins / Q000032:analysis
D000932:Antiemetics; D001798:Blood Proteins; D005719:gamma-Globulins; D003520:Cyclophosphamide
Erfahrungen mit ultrahohen Cyclophosphamid-Dosen an 42 Kranken mit soliden und lymphoretikulären Tumoren.